Aurobindo Pharma plans to launch the products manufactured at its Hyderabad facility soon in the US market
New Delhi: Aurobindo Pharma on Wednesday said it has received final approval from the US health regulator for its generic Nevirapine tablets and oral suspension used for treating human immunodeficiency virus (HIV), reports PTI.
The company has received final approval from the United States Food and Drug Administration (USFDA) for its Nevirapine tablets in the strength of 200 mg and Nevirapine oral suspension in the strength of 50 mg/5ml, Aurobindo Pharma said in a statement.
The company plans to launch the products manufactured at its Hyderabad facility soon in the US market, it added.
According to IMS health data the products have a market size of about $125 million for the twelve months ending December 2011, Aurobindo Pharma said.
Nevirapine tablets and oral suspension are generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune tablets and oral suspension in the same strengths.
"The products are indicated as part of antiretroviral combination therapy for the treatment of HIV infected adults," it added.
The company said it currently has 151 abbreviated new drug application (ANDA) approvals from the USFDA.
Shares of Aurobindo Pharma were today trading at Rs111.50 in the afternoon trade on BSE, up 1.23% from its previous close.
During FY12, Canara Bank's total revenues, including interest income, rose 31% to Rs33,920.15 crore from Rs25,834.14 crore a year ago
Mumbai: State-run Canara Bank on Wednesday posted 17% dip in its consolidated net profit at Rs3,341.69 crore for 2011-12 fiscal, reports PTI.
For the year ended March 2011, the bank had a net profit of Rs4,034.19 crore, it said in a filing to the BSE.
During 2011-12, Canara Bank's total revenues, including interest income, rose 31% to Rs33,920.15 crore from Rs25,834.14 crore in the previous fiscal.
The banks's net interest income fell by 1% to Rs7,656.17 crore year-on-year, while non-interest income showed a rise of 10% at Rs3,104.51 crore.
In the reported year, its operating profit stood at Rs5,941.80 crore against Rs5,973.14 crore in the comparable period.
Shares of Canara Bank were trading at Rs386.15, down 1.5% from its previous close on the BSE.
Facts of each case will decide which orders can be appealed against